Optiver Holding’s Catalyst Pharmaceutical CPRX Stock Holding History

Optiver Holding’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-364	Closed	-$7.17K	–	2576
2025 Q3	$7.17K	Buy	+364	New	+$7.49K	﹤0.01%	1499

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Optiver Holding's CPRX Position: Q4 2025 in Review

Optiver Holding sold out of Catalyst Pharmaceutical (CPRX) in Q4 2025, closing a stake of 364 shares — an estimated $7.17K sold.

Optiver Holding first reported a position in CPRX in Q3 2025 and held it in 1 quarter. The position peaked at $7.17K in Q3 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

Optiver Holding reported no remaining Catalyst Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Optiver Holding sold 364 Catalyst Pharmaceutical shares in Q4 2025, an estimated $7.17K.
Optiver Holding first reported a position in Catalyst Pharmaceutical in Q3 2025 and held it in 1 quarter.
Optiver Holding's Catalyst Pharmaceutical position peaked at $7.17K in Q3 2025.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on Optiver Holding's 13F filing for Q4 2025, filed 17 Feb 2026.